Amy S. Chappell, MD

Dr. Chappell is a board certified neurologist with special competence in child neurology and a board-certified lifestyle medicine physician. She graduated from Indiana University Medical School; completed 2 years of pediatrics and an epilepsy fellowship at the Johns Hopkins Medical Center; and completed a neurology residency at Indiana University Medical Center. She was a full-time faculty member in the neurology department of the Indiana University Medical Center until being hired as a clinical research physician by Eli Lilly and Company. She retired from Lilly Research Laboratories in January,2014, after 25 years in clinical research. She designed and conducted clinical trials through all phases of development in a broad range of neurological disorders.  She was the lead physician for the development of duloxetine for fibromyalgia which resulted in an FDA approval. During her career at Lilly Dr. Chappell continued to practice neurology at the Indiana University Medical Center. She now practices neurology as a volunteer at the Neighborhood Health Clinic in Naples, FL.  She is a fellow of the American Academy of Neurology and the American College of Sports Medicine, board member of the American Society of Experimental Neurotherapeutics, and a member of the Child Neurology Society, the American College of Lifestyle Medicine and the Society of Tennis Medicine and Science.  Her current position is Chief Medical Officer of Eliem Therapeutics and Neurology Consultant for Carnot Therapeutics.